Liposomes co-delivery system of doxorubicin and astragaloside IV co-modified by folate ligand and octa-arginine polypeptide for anti-breast cancer

Doxorubicin (DOX) is one of the core drugs in triple-negative breast cancer (TNBC) chemotherapy, but its resistance has severely limited its clinical application. Our previous study found that astragaloside IV (AS-IV) has a good reversal effect on doxorubicin resistance. In order to encapsulate DOX...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Guijuan, Wang, Chengxiang, Liu, Bo, Wu, Mangang, Huang, Yuangyuan, Guo, Yuying, Ma, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Chemistry
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050494/
https://www.ncbi.nlm.nih.gov/pubmed/35496626
http://dx.doi.org/10.1039/c9ra09040a

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9050494/
https://www.ncbi.nlm.nih.gov/pubmed/35496626
http://dx.doi.org/10.1039/c9ra09040a

Ejemplares similares